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Membrane perturbationThe prion protein (PrP) is essential for the pathogenesis of prion disease. PrP has been detected in the cytosol
of neurons and transgenic mice expressing PrP in the cytosol (cyPrP) under a pan-neuronal promoter
developed rapid cerebellar granule neuron degeneration. Yet, it remains unclear whether cyPrP is capable to
cause toxicity in other neuronal populations. Here, we report that transgenic mice expressing cyPrP in the
forebrain neurons developed behavioral abnormalities including clasping and hyperactivity. These mice had
reduced thickness in cortex and developed astrogliosis in hippocampal and cortical regions. Moreover, cyPrP
in these mice was recognized by the A11 anti-oligomer antibody and was associated with the hydrophobic
lipid core of membranes, indicating that cyPrP oligomer caused membrane perturbation contributes to cyPrP
neurotoxicity. Together, our results clearly revealed that cyPrP is able to cause toxicity in different neuronal
populations, supporting a role of cyPrP in PrP-mediated neurodegenerative disorders.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Prion diseases are a group of neurodegenerative disorders
characterized by the conversion of normal prion protein (PrPC) to a
pathogenic conformation (PrPSc) [1–4]. Previous studies established
that the expression of PrPC is indispensable for prion disease [5–7].
Moreover, these studies also indicate that an alteration in PrPC
metabolism contributes to neurotoxicity.
Besides its normal cell surface localization, PrP has been detected in
the cytosol of neurons in wild-type animals [8]. The cytosolic
appearance of PrP has been attributed to retro-translocation of
misfolded PrP from the endoplasmic reticulum (ER) [9–11], impaired
import into ER due to the inefﬁciency of PrP signal sequences [12], or
pre-emptive quality control in the ER [13,14]. We previously reported
that transgenic mice expressing PrP in the cytosol (cyPrP) under its
own pan-neuronal promoter developed rapid cerebellar granule
neuron degeneration [15]. The lack of detectable toxicity in other
brain regions led to the question of whether cyPrP toxicity could affect
other neurons. Moreover, the controversy over cyPrP neurotoxicity is
further deepened by conﬂicting results from cell culture studies, from
toxic [12,15–17], to not toxic [18,19], or even protecting certain types of
cells against Bax induced apoptosis [20,21]. In prion disease, the
neurotoxicity involves different neuronal populations [22–25]. Should
cyPrP play any role in the pathogenesis of prion disease, it must be able
to cause toxicity in other neuronal populations in an in vivo setting.ll rights reserved.In this study, we generated transgenic mice expressing cyPrP
under the control of a tetracycline-responsive promoter, in which
the transgene expression requires the binding of tetracycline-
transactivator (tTA) to the promoter in the absence of tetracycline
(known as the “Tet-OFF system”). We crossed inducible cyPrP
transgenic mice with mice expressing tTA under the control of
calcium-calmodulin-dependent kinase II (CamKII) promoter [26],
creating double transgenic mice expressing cyPrP in the forebrain.
This strategy avoided the rapid cyPrP-evoked cerebellar degeneration,
allowing us to determinewhether cyPrP is toxic to other neurons after
an extended period of time. Here, we report that cyPrP indeed causes
toxicity in forebrain neurons. In addition, cyPrP is recognized by the
A11 anti-oligomer antibody and binds to the hydrophobic lipid core of
membranes, which supports the hypothesis that oligomeric cyPrP
perturbs lipid membranes and causes neurotoxicity.
2. Materials and methods
2.1. Generation of transgenic mice
Puriﬁed DNA fragment containing cyPrP coding sequences under
the regulation of a tetracycline-responsive bi-directional promoter
(designated as: pBI-cyPrP-Gal, Fig. 1A) was microinjected into
fertilized FVB/N mouse oocytes. Pups were screened for founders by
PCR of tail DNAwith two pairs of primers. The β-Gal primers amplify a
sequence within the β-galactosidase gene. The PrP primers amplify a
sequence between cyPrP and the minimal CMV promoter (PminCMV,
Fig. 1A).
Fig. 1. Characterization of tetracycline-inducible transgenic mice expressing cyPrP in
the forebrain. (A) The pBI-cyPrP-Gal construct. (B) Double transgenic mice (tTA+/−;
pBI-cyPrP-Gal+/−) from two transgenic lines (#27 and #33) and a control mouse (tTA
+/−; pBI-cyPrP-Gal−/−) were switched to dox-free food at 6 weeks of age and
sacriﬁced when 8 weeks old. The expression of the β-Gal gene was monitored by
measuring β-Gal activity in forebrain and hindbrain lysates as indicated. (C) Beta-Gal
activity was measured in forebrain and hindbrain lysates of double and single trans-
genic littermates fed with or without dox as indicated. (D) The expression of cyPrP was
measured by immunoblot analysis with 3F4 antibody. F, forebrain; H, hindbrain.
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GACCTCC 3′; BI2722, 5′ CACGCAACTCGCCGCACATCTGAACTT 3′.
The PrP primers are: BI459, 5′ AACCTCCCACACCTCCCCCT-
GAACCTG3 ′; BI944A, 5′ GGCAACGACTGGGAGGACCGCTACTAC 3′.
2.2. Determination of transgene dosage with radioactive PCR
PCR reactionwas carried out in 10 μl volumewith ∼40 ng tail DNA,
PrP primers, and mouse cyclophilin primers (as internal control) in
20 mM Tris pH 8.4, 50 mM KCl, 2% formamide, 0.2 mM dNTP, 1 μM
each of the primers, 0.5 U of Taq polymerase, and 1 μCi α-P32-dCTP.
After 20 cycles, half of the sample was loaded on a 4% polyacrylamide
denaturing gel and subjected to electrophoresis. Results were
quantiﬁed by a Storm PhosphorImager System (Molecular Dynamics).
2.3. Behavior analysis
Fourteen double transgenic mice (tTA+/−; pBI-cyPrP-Gal+/−)
and 11 single transgenic control mice (tTA−/−; pBI-cyPrP-Gal+/−)
from two transgenic lines, which went through the same transgene
induction regime of switching food containing doxycycline (dox-food)
(Bio-Serv) to regular mouse food at 6 weeks of age, were kept at the
mouse behavior testing facility at Ohio State University formore than a
month before conducting the test. Two double transgenic mice died
during the course of testing and all available mice were subjected to
full panel of tests as previously described [27].
The open ﬁeld test was conducted in a test chamber that was
enclosed in a sound and light attenuating cabinet and consisted of a
60 cm3 clear Plexiglas arena lined with corncob bedding. The arena
was surrounded by a series of infrared lights for tracking mouse
movement in three dimensions. Between each test, the chamber was
rinsed thoroughly with a 70% ethanol solution and the bedding was
changed. Each test session was 30 min in duration and the results
were generated by the PAS software package (San Diego Instruments,
San Diego, CA, USA). The total locomotor activity (number of beam
breaks), percentage of activity in the periphery versus the center of
the arena, and the total number of rears served as the dependent
measures.For the tail pinch test, the mouse was pinched at approx 2 cm from
the base of tail and scored as: 0, no reaction; 1, look back, pull forward
or light squeal; 2, twitch (muscle tension); 3, aggressive or vocal
response. For the toe pinch test, the mouse was pinched at the middle
hind left toe and scored as: 0, no reaction; 1, slight withdrawal; 2,
moderate withdrawal (not brisk); 3, brisk, rapid withdrawal; 4, very
rapid, repeated withdrawal.
For tail suspension test, the mouse was suspended ∼30 cm above
the surface of a table for 15 s with each 2-second clasping counted as 1
point. Eleven double transgenic mice (tTA+/−; pBI-cyPrP-Gal+/−)
and 11 single transgenic control mice (tTA−/−; pBI-cyPrP-Gal+/−)
that went through the same induction regime of switching dox-food
to regular mouse food at the age of 6 weeks were subjected to the test.
2.4. Membrane association, solubility and immunoblot analysis
The cyPrP membrane association analysis was performed as
previously described [28]. Brieﬂy, post-nuclear supernatants containing
100 μg of proteinwere separated on a discontinuous iodixanol gradient
[28,29] and 200 μl fractions were collected. For membrane extractions,
300 μg post-nuclear supernatant was centrifuged at 346,000 g for
30 min at 4 °C. The pellet was re-suspended in a solution containing
0.5MNaHCO3, pH 11, or 1MKCl plus 10mMNaOH and subjected to the
iodixanol gradient separation. The solubility analysis was performed as
previously described [28] except that the centrifugation of induced
homozygous transgenicmicewas carriedout at 100,000 g for 1 h at 4 °C.
Subcellular fractionation of neuronal membranes was performed as
previously described [28,30]. The presence of cyPrP and synaptophysin
was determined by immunoblot analysis with the 3F4 anti-PrP
antibody (Covance) and an anti-synaptophysin antibody (Sigma).
Quantiﬁcation was performed on a Storm PhosphorImager System
(Molecular Dynamics).
2.5. Histological analysis
Hematoxylin & eosin staining (H&E) was performed with Harris
hematoxylin (Sigma) and eosin Y (Fisher). Immunohistochemistry
was performed as previously described (27). CyPrP was detected with
a mouse 3F4 antibody (Signet) at 1:1000. Rabbit anti-GFAP antibody
(DAKO) was used at 1:4000. Antigen Amplify system (Prohisto Lab)
was used as the manufacturer suggested to increase sensitivity of
detection. Chicken anti-neuroﬁlament heavy chain (NF-H) antibody
(EnCor Biotech) was used at 1:1000, and donkey anti-chicken
secondary antibody (Jackson ImmunoResearch Laboratories) was
used at 1:500. ABC and DAB kits were purchased from the Vector Lab.
For immunoﬂuorescence staining, cyPrP was detected with 3F4
antibody (4mg/ml, Covance) at 1:1500. Rabbit anti-calnexin antibody
(Stressgen) was used at 1:1000. Alexa Fluor 488 goat anti-mouse IgG
(1:500) and Alexa Fluor 594 goat anti-rabbit IgG (1:500) (Invitrogen)
were used as secondary antibodies. Antigen Amplify system (Prohisto
Lab) was used to increase sensitivity of detection. Incubations with
primary and secondary antibodies were carried out at 4 °C for 48 and
1 h, respectively. After washing twice with PBS, slides were incubated
with 100 ng/ml 4,6-diamidino-2-phenylindole (DAPI) (Sigma) in PBS
for 10 min and washed three times with PBS. Coverslips were
mounted on glass slides, and staining was visualized with an Olympus
IX81 inverted microscope.
2.6. Beta-galactosidase (β-Gal) staining and activity
For staining, brain hemispheres were rinsed with ice-cold PBS pH
7.8, ﬁxed at 4 °C for 1 h in 2% paraformaldehyde, 0.2% glutaraldehyde,
0.02% NP-40, and 0.01% deoxycholate. After three PBS rinses, brain
hemispheres were stained at 37 °C for 4 h with X-Gal solution (5 mM
KFeCN, 2 mM MgCl2, 0.02% NP-40, 0.01% Deoxycholate, 1 mg/ml X-
GAL), and post-ﬁxed with 4% paraformaldehyde for 2 h.
Fig. 2. Characterization of CyPrP in the inducible transgenic mice. Forebrain detergent
lysate from an induced heterozygous transgenic mouse were separated into super-
natant (S) and pellet (P) fractions, and the presence of cyPrP was determined by
immunoblot analysis with the 3F4 anti-PrP antibody. The same blot was re-probed with
7A12 antibody to determine total PrP. Arrow points at the expected position of cyPrP.
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180 min with 1 ml LacZ solution (60 mM Na2HPO4, 40 mM NaH2PO4
pH 6.95, 10 mM KCl, 1 mM MgSO4; and freshly added 50 mM β-
mercaptoethanol) and 200 μl substrate solution (60 mM Na2HPO4,
40 mM NaH2PO4 pH 6.95; and freshly added 2 mg/ml o-Nitrophenyl
β-D-Glactopyranoside). The reaction was stopped by adding 0.5 ml of
1 M Na2CO3 and OD was measured at 420 nm.
2.7. Detection of cyPrP oligomers
Mouse forebrains were homogenized in Mg2+ and Ca2+ free PBS
(1:10 (w/v)). To prepare lysates for immunoprecipitation, stock
solutions were added to 100 μl homogenate to reach ﬁnal concentra-
tions of 10 mM Phosphate buffer, pH 7.4, 150 mM NaCl, 1% NP-40, 1%
Deoxycholate, 0.1% SDS, and 1× complete protease inhibitors (Roche) in
aﬁnal volumeof 150 μl. The lysateswere kept on ice for 10min, followed
by 10 minute sonication in a cup-hold sonicator and pre-cleared by
rotating at room temperature for 40 min in the presence of 20 μl of
Protein G magnetic beads (Dynabeads, Invitrogen). The pre-cleared
lysates were rotated at 4 °C overnight in the presence of 7 μg of the A11
anti-oligomer antibody (BioSource, Invitrogen), followed by incubation
with 40 μl of Protein Gmagnetic beads at room temperature for 40min.
The beads were then washed and eluted according to manufacturer
suggested protocol. Samples were subjected to SDS-PAGE and immu-
noblot analysis.
3. Results
3.1. Characterization of tetracycline-responsive transgenic mice
expressing cyPrP
We generated transgenic mice expressing murine cyPrP under the
regulation of a tetracycline-responsive bi-directional promoter. This
promoter, as shown in Fig. 1A, contains a tetracycline-responsive
element (TRE) ﬂanked by two identical minimal CMV promoters
(PminCMV) driving cyPrP and β-Gal expression respectively. The
transgene expression is regulated by the tTA transcription factor of the
“Tet-off system”. The widely used 3F4 epitope, an epitope derived
from hamster PrP, was engineered in murine cyPrP, allowing us to
readily distinguish cyPrP from endogenous murine PrPC.
Six transgenic founders were identiﬁed and all of them were
crossed with FVB/N mice expressing tTA under the control of the
CamKII promoter [26]. The pregnant mice were supplied with dox-
food to suppress transgene expression. Once double transgenic
offspring (tTA+/−; pBI-cyPrP-Gal+/−) were identiﬁed, dox-food
was removed at 6 weeks of age and the expression of cyPrP and β-Gal
wasmonitored after 2 weeks of induction. Using a β-Gal activity assay,
we identiﬁed two lines of mice (lines 5 and 33) expressing transgene
at different levels. Fig. 1B shows that β-Gal activity was detected in the
forebrain of a double transgenic mouse from line 33, but not in a
double transgenic mouse from line 27. Similarly, no β-Gal activity was
detected in a control single transgenic mouse containing only the tTA
transgene. The whole brain β-Gal staining revealed that the β-Gal
expression was largely conﬁned to the forebrain (Supplemental
Fig. S1), consistent with CamKII promoter-driven tTA expression
pattern [26]. Transgene expression was regulated by dox and no β-gal
activity or cyPrP expression was detected in double transgenic mice
fed with dox-food (Fig. 1C and D). When dox was removed, cyPrP and
β-Gal were expressed and the expression was almost exclusively in
the forebrain (Fig. 1C and D). The equal loading of the gel (Fig. 1D) was
veriﬁed by total protein stain of the blot (data not shown).
To determine the aggregation status of cyPrP in these mice, we
separated forebrain detergent lysates prepared from induced double
transgenic mice into supernatant and pellet fractions. The majority of
cyPrP was detected in the pellet fraction (Fig. 2, left panel). The same
blot was re-probed with 7A12 antibody that recognizes bothendogenous PrP and cyPrP transgene [31]. Clearly, most of the
heterogeneously glycosylated endogenous PrP was soluble and
appeared in the supernatant (Fig. 2, right panels). Notably, the
aggregated cyPrP could not be reliably detected with 7A12 antibody,
suggesting a low cyPrP level compared to endogenous PrP. In these
induced mice that are heterozygous for the cyPrP transgene, cyPrP
was sensitive to proteinase K (PK) digestion (data not shown).
3.2. Mice expressing cyPrP in the forebrain developed behavioral
abnormalities
When transgene expression was suppressed by feeding mice with
dox-food, no difference was noticed between double transgenic mice
(tTA+/−; pBI-cyPrP-Gal+/−) and control mice (pBI-cyPrP-Gal only,
tTA only or wild-type mice). When cyPrP expression was induced by
switching from dox-food to regular diet, behavioral phenotypes
emerged. Inducing cyPrP expression for 2 weeks led to clasping, a
common neurodegenerative phenotype, in both transgenic lines 5 and
33 (Fig. 3A).
To determine other behavioral abnormalities, double transgenic
mice (both lines 5 and 33) and their single transgenic control
littermates were induced and subjected to a battery of behavior tests.
The open ﬁeld test revealed that induced double transgenic mice had
signiﬁcantly increased locomotor activity compared to control mice
(Fig. 3B), which was consistent with our daily observation that many
induced transgenic mice developed stereotypical circling. The signiﬁ-
cance of the openﬁeld test resultsmight be compromised somewhat by
a small number of induced double transgenic mice that had obviously
reduced locomotor activity and remained inactive. The observation of
hyper- and hypoactive mice in both transgenic lines 5 and 33 ruled out
the possibility that this phenotype results from the random transgene
integration. Nonetheless, the induced transgenicmice as awhole group
had a statistically signiﬁcant increase in locomotor activity.
The hyperactivity of these mice interfered with the interpretation
of other behavior tests. For example, induced double transgenic mice
had reduced numbers of rears and showed a preference for the light
chamber during the light–dark preference test (data not shown).
Although the differences were statistically signiﬁcant, the fact that
several induced transgenic micewere continuously circling during the
testing period, rather than exploring the arena, precludes a conclusive
interpretation of the results.
In contrast, a signiﬁcant difference in their response to tail and toe
pinch was observed between control and cyPrP-expressing mice, with
induced double transgenic mice reacting more violently (Fig. 3C). This
phenotype may have contributed to the higher tendency for double
transgenic mice, both males and females, to initiate ﬁght with their
littermates, which was observed during our daily monitoring.
When these mice were sacriﬁced, we compared the brainweight of
double transgenicmice to that of single transgenicmice (tTA−/−; pBI-
cyPrP-Gal+/−), which had gone through the same induction regime.
The brains of cyPrP-expressing double transgenic mice were signiﬁ-
cantly lighter compared to control mice, while there is no signiﬁcant
Fig. 4. More severe toxicity associated with homozygous transgenic mice (tTA+/−,
pBI-cyPrP-Gal+/+). (A) Homozygous (+/+) and heterozygous (+/−) transgenic
littermates at 4 weeks of age. The transgene expression was never suppressed in these
mice and they were always kept in the same cage since birth. (B) Brain images of an
induced homozygous transgenic mouse (Tg (+/+)) and its single transgenic littermate
(control) sacriﬁced at 6 months of age. Bars represent 1 mm. (C) CyPrP in the forebrain
of induced hetero- (+/−) or homozygous (+/+) mice were detected by immunoblot
analysis with the 3F4 antibody. Equal loading was veriﬁed by re-probing the same blot
with an antibody against β-actin. (D) Serial dilutions of forebrain lysates of an induced
homozygous transgenic mouse and a knock-in mouse in which endogenous PrP was
replaced by mouse PrP with the 3F4 epitope. The total protein concentration was
indicated and PrP was detected by immunoblot analysis with the 3F4 antibody. Arrow
points at cyPrP. (E) Forebrain lysates of homozygous transgenic mice were separated
into supernatant (sup) and pellet (ppt) fractions by a 1-hour 100,000 g centrifugation.
The presence of cyPrP was determined by immunoblot analysis with the 3F4 antibody.
Fig. 3. Forebrain toxicity in induced transgenic mice expressing cyPrP. Pregnant mice
and pups were supplied with dox-food until 6 weeks of age and then switched to
normal food to induce transgene expression in double transgenic mice (tTA+/−; pBI-
cyPrP-Gal+/−). Among 11 double transgenic mice, 8 mice were from line 33 and 5
mice were from line 5. Single transgenic littermates (tTA−/−; pBI-cyPrP-Gal+/−)
that went through the same induction regime were used as controls. (A) Picture and
score of tail suspension test. Error bars represent standard error and the differences
are statistically signiﬁcant, pb0.05 at 2 weeks and pb0.01 at remaining time points.
(B) Total locomotor activity as indicated by the number of beam breaks. (C) Scores of
tail and toe pinch. (D) The brain and body weight of induced heterozygous double
transgenic mice and their single transgenic littermates. (E) A representative pair of
double transgenic mouse (Tg(+/−)) and single transgenic littermate (control)
showing the difference in the cortex thickness. Bars represent 1 mm.
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these brains were dissected sagittally, a noticeably thinner cortex was
observed in induced double transgenic mice (Fig. 3E).
3.3. Neurodegeneration in induced cyPrP homozygous mice
In order to determinewhether an increased cyPrP dosage leads to a
more severe toxicity, we generated homozygous double transgenic
mice from transgenic line 33. Heterozygous double transgenic mice
(tTA+/−; pBI-cyPrP-Gal+/−) were mated with single transgenic
mice (tTA−/−; pBI-cyPrP-Gal+/−), and the pregnant females were
separated and remained on regular diet. Thus, the transgene
expression was never suppressed in these pups. We compared the
phenotype among littermates that were without cyPrP transgene
(wild-type), with tTA and a single copy of cyPrP transgene (hetero-
zygous, tTA+/−; pBI-cyPrP-Gal+/−), or with two copies of cyPrP
transgene (homozygous, tTA+/−; pBI-cyPrP-Gal+/+).Although both heterozygous and homozygous mice developed
stereotypical circling and clasping phenotype, the homozygous
transgenic mice were much smaller compared to wild-type or
heterozygous transgenic littermates (Fig. 4A), which was noticeable
from 14 days after birth. No obvious difference in food intake was
observed, and the body size difference was not obvious among
heterozygous mice (tTA+/−; pBI-cyPrP-Gal+/−), wild-type mice,
and single transgenic mice containing only tTA transgene (tTA+/−;
pBI-cyPrP-Gal−/−) or one or two copies of the pBI-cyPrP-Gal
transgene (tTA−/−; pBI-cyPrP-Gal+/− or tTA−/−; pBI-cyPrP-Gal
+/+), suggesting that the body size difference is due to the toxic
effect of higher amount of cyPrP. In accordance with this notion, the
tapering of cortex appeared to be more severe in homozygous double
transgenic mice (Fig. 4B).
The cyPrP level in homozygous mice was about 3 fold higher
compared to heterozygous littermates (Fig. 4C and Supplemental Fig.
S2), which is higher than what would be predicted based on gene
dosage, indicating that, once above certain levels, more cyPrP escapes
degradation. However, the amount of cyPrP in homozygous mice was
still a small fraction of endogenous PrPC. Using serial dilutions of
forebrain homogenates, we compared the cyPrP level in homozygous
micewith that of knock-inmice expressingwild-type PrP with the 3F4
epitope (Jackson, W. and Lindquist, S. unpublished data) (Fig. 4D).
PhosphorImager quantiﬁcation revealed that the cyPrP level was less
than 10% of the endogenous PrP.
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aged homozygous mice (Fig. 4E and Supplemental Fig. S3), a
signiﬁcant portion of cyPrP was soluble in 24-day-old homozygous
transgenic mice (Fig. 4E and Supplemental Fig. S4), suggesting a
higher aggregation tendency of cyPrP in aged animals. PK digestion
analysis revealed a slight increase in cyPrP PK-resistance in bothFig. 5. Neurotoxicity in the cortical and hippocampal regions. (A and B) CyPrP in wild-
type and transgenic mouse brains were stained with 3F4 anti-PrP antibody (brown). (C
and D) Immunoﬂuorescence staining of cyPrP in hippocampal CA1 region of wild-type
and transgenicmice as indicated. (E and F) H&E staining of the cortical and hippocampal
regions of wild-type and transgenicmice brains. (G andH)Highmagniﬁcation images of
ﬁgures D and E as indicated by the inserts. (I and J) Cortical and hippocampal regions of
wild-type and transgenic brains stainedwith an anti-GFAP antibody (brown). (K) A high
magniﬁcation image of transgenic mouse cortical region stained with an anti-GFAP
antibody (brown). (L andM) Brains of wild-type and transgenic micewere stained with
an anti-neuroﬁlament heavy chain antibody (brown). (N and O) High magniﬁcation
images of wild-type and transgenic mouse cortical regions stained with an anti-
neuroﬁlament heavy chain antibody (brown). In all images, nuclei were counter stained
with hematoxylin (blue). Images were taken using an Olympus IX81 inverted
microscope and the settings were exactly the same for images in the same group. WT,
wild-type mouse; Tg, cyPrP-expressing double transgenic mouse.young and old homozygous mice. A 15 kDa cyPrP fragment was
detected after a 1-hour 2 μg/ml PK digestion at 37 °C, whereas
endogenous PrP remained PK sensitive (Supplemental Fig. S5).
Although the PK-resistance is much lower compared to pathogenic
PrPSc form, the increase of PK-resistance in a speciﬁc cyPrP fragment
may indicate the formation of ordered aggregates.
Collectively, these results suggest that a small amount of cyPrP is
sufﬁcient to cause neurotoxicity and the toxicity is dependent on the
level of cyPrP.
3.4. Neurotoxicity in cortex and hippocampus
Histology analysis revealed that there is no overt brain structure
abnormality in hetero- or homozygous mice in which transgene
expressionwas never suppressed (data not shown), indicating that the
levels of cyPrP expression in these mice did not affect brain
development. CyPrP and various neuronal markers were stained to
determine the relationship between cyPrP expression and neurotoxi-
city. Similar to reported expression pattern of CamKII promoter-driven
tTA [32], the cyPrP was detected in hippocampus and cortex by the
3F4 antibody (compare Fig. 5A and B). Using immunoﬂuorescence
staining, we detected cyPrP in the processes and cell bodies of hip-
pocampal neurons (compare Fig. 5C and D), while no nuclear
accumulation or formation of perinuclar aggresome was detected
(Fig. 5D). Moreover, we did not observe any extracellular cyPrP
accumulation in either young or aged mice, indicating that cyPrP
neurotoxicity is cell autonomous.
More condensed nuclei were observed in cortical and hippocampal
neurons of cyPrP-expressing transgenic mice (compare Fig. 5E and F,
Fig. 5G and H), and Glial ﬁbrillary acidic protein (GFAP) staining
revealed astrogliosis in both regions (compare Fig. 5I and J, Fig. 5K is a
high magniﬁcation of transgenic mouse cortical region). In addition, a
reduced neuroﬁlament staining was observed in the cortical and
hippocampal regions of cyPrP-expressing transgenic mice (compare
Fig. 5L and M), which was more evident under a high magniﬁcation
(compare Fig. 5N and O). Together, these results revealed that the
neurotoxicity is in the cortical and hippocampal regions, supporting
the relationship between cyPrP expression and neurotoxicity.
3.5. A portion of cyPrP is associated with the hydrophobic lipid core of
membranes
To determinewhether cyPrP in thesemice are associated with lipid
membranes, we performed iodixanol gradient analysis, in which the
forebrain homogenates were loaded at the bottom of the gradient and
membrane-bound PrP would migrate to the top. Our result indicated
that a portion of cyPrP in the double transgenic mice was membrane-
bound, migrating to top fractions similar to GPI-anchored endogenous
PrP (Fig. 6A), while the cytosolically localized GAPDH (glyceralde-
hydes-3-phosphate dehydrogenase) remained at the bottom.
The cyPrP's membrane association was supported by co-staining
cyPrP with calnexin, an ER membrane protein. We found that a
signiﬁcant portion of cyPrP in the cell body was co-localized with
calnexin (Fig. 6B), while no co-localization was detected for cyPrP in
neuronal processes (Fig. 6B, indicated by a white arrowhead). The
possible cyPrP's association with plasma membrane was not clearly
detected using this method, which may be attributed to reasons that
only a portion of cyPrP is membrane associated (Fig. 6A and D) and/or
that plasma membrane associated proteins are difﬁcult to stain in
parafﬁn-embedded sections. Nevertheless, the co-localization of
cyPrP with calnexin is in accordance with result of gradient analysis,
that is, a portion of cyPrP is associated with membranes.
We also analyzed which subcellular membrane cyPrP is associated
with in these mice by separating neuronal membranes according to a
standard protocol [28,30] (Fig. 6C). S1 and P2 represent post-nuclear
supernatant and crude membranes respectively, P3 is enriched with
Fig. 6. The interaction between cyPrP and lipid membranes. (A) Post-nuclear supernatant prepared from the forebrain of an induced heterozygous transgenic mouse (pBI-cyPrP-
Gal+/−; tTA+/−) was separated by the iodixanol gradient. The presence of cyPrP in each fraction was detected by the 3F4 antibody. The same blot was re-probed by POM1 anti-
PrP antibody to identify membrane associated endogenous PrP, and an anti-GAPDH antibody to identify cytosolic GAPDH protein. Number represents fractions from top to the
bottom. F, forebrain; H, hindbrain; arrow indicates the position of cyPrP; asterisk indicates a non-speciﬁc reactive band that was present in both forebrain and hindbrain lysates.
(B) CA1 region of a transgenic mouse brain was stained with antibodies against cyPrP (green) and ER membrane protein calnexin (red). Nuclei were stained with DAPI (blue).
Yellow color in the merged image indicates the co-localization between calnexin and cyPrP in the cell body. White arrowhead points to cyPrP in the neuronal process that is not
co-localized with calnexin. (C) The presence of cyPrP in different neuronal subcellular membranes. CyPrP and synaptophysin were detected by immunoblot analysis, and the total
protein of each fraction is 10 μg. (D) Post-nuclear supernatant prepared from an induced homozygous transgenic mouse was subjected to no extraction, extraction with 1 M KCl
plus 10 mM NaOH or with 0.5 M NaHCO3, pH 11, and then separated by the iodixanol gradient. CyPrP was detected by immunoblot analysis with 3F4 antibody.
560 X. Wang et al. / Biochimica et Biophysica Acta 1792 (2009) 555–563light membranes and microsomes, LP1 represents synaptosomal
membranes, and LP2 represents a synaptic vesicle-enriched fraction
[30,33,34]. Notably, cyPrP was enriched in microsomal (P3) and
synaptosomal (LP1) membrane fractions (Fig. 6C, top panel). In
contrast to neuronal membrane protein synaptophysin, very little
cyPrP was detected in the synaptic vesicle-enriched LP2 fraction (Fig.
6C). These results suggest that cyPrP in these mice are associated with
plasma and ER membranes.
To determine whether cyPrP in these mice is associated with the
hydrophobic lipid core of membranes, we extracted membranes with
a buffer containing 1 M KCl plus 10 mM NaOH. As shown in Fig. 6D, a
portion of cyPrP remained membrane associated after the extraction
(Fig. 6D, middle panel). A more stringent condition, extracting
membranes with 0.5 M NaHCO3 at pH 11, was also performed and,
still, some cyPrP remained membrane-bound (Fig. 6D, bottom panel).
High salt and alkaline extraction condition will remove all the
peripheral membrane associated proteins from lipid bilayer. More-
over, we previously showed that aggregated cyPrP in the forebrain of
straight transgenic mice remained at the bottom fractions after
extraction [28], which suggests that the migration of cyPrP to top of
the gradient is not due to cyPrP aggregation caused density change.
Thus, these results indicate that cyPrP is associated with the
hydrophobic lipid core of membranes in the inducible transgenic
mice, which is in agreement with our hypothesis that cyPrP caused
membrane perturbation leads to neurotoxicity [28].
3.6. CyPrP is recognized by the A11 anti-oligomer antibody
Recent studies have suggested that a common ordered oligomeric
species adopted by numerous amyloidogenic proteins often happens
on the amyloid ﬁber formation pathway [35,36]. Instead of mature
amyloid ﬁbers, the soluble oligomeric species permeabilizes lipid
bilayer and causes cytotoxicity [37,38]. To determine whether cyPrP
forms ordered oligomer, we used protein G-coated magnetic beadstogether with an anti-oligomer antibody (A11 antibody), which
speciﬁcally recognizes oligomer formed by various amyloidogenic
proteins including PrP [35], to pull up cyPrP oligomers present in the
forebrain lysates. Notably, cyPrP was pulled up by the A11 antibody
and detected by immunoblot analysis with the 3F4 anti-PrP antibody
(Fig. 7A, lane 3). When the same experiment was performed without
adding the A11 antibody, cyPrP was not detected (Fig. 7A, lane 1),
ruling out the possibility of non-speciﬁc binding. Neither was another
control in which a single transgenic littermate containing only pBI-
cyPrP-Gal transgene was used (Fig. 7A, lane 2), supporting that the
band detected by the 3F4 antibody was indeed cyPrP.
To compare the amount of cyPrP oligomer in the induced
homozygous and heterozygous transgenic mice, the same experiment
was repeated using forebrain lysates prepared from induced homo-
zygous or heterozygous transgenicmice (Fig. 7B, top panel). Our result
showed that the amount of cyPrP oligomer was higher in the
homozygous mice (Fig. 7B, top panel, compare lanes 3 and 5). Since
the age of mice used in this analysis was comparable, 15 and
16 months respectively, this difference is most likely not due to the
age of animals. Instead, the formation of amyloid oligomer appears to
be dependant on the cyPrP levels in the brain, which also correlates
with the more severe toxicity seen in homozygous mice.
The SDS-PAGE migration pattern of cyPrP pulled up by the A11
antibody (Fig. 7B, top panel, lanes 3 and 5) was exactly the same as
cyPrP in the forebrain lysates detected directly by immunoblot analysis
(Fig. 7B, top panel, lane 6). In addition, when the same blot was re-
probed by the POM1 anti-PrP antibody that recognizes all PrPs [39],
almost no endogenous PrPwas detected in the pull-up samples (Fig. 7B,
bottom panel). Since the input of the pull-up experiment was 50 times
greater than that used in the control (Fig. 7B, bottom panel, lane 6), the
lack of endogenous PrP detection in the pull-up samples supported the
speciﬁcity of this analysis. Together, these results indicate that, in vivo,
cyPrP forms ordered amyloid oligomer and the amount of cyPrP
oligomer appeared to be associated with the severity of neurotoxicity.
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Our results of inducible transgenic mice provided several novel
ﬁndings of cyPrP neurotoxicity. First, we have clearly showed that
cyPrP-evoked toxicity is not restricted to cerebellar granule neurons.
In the inducible mice, it causes toxicity in different forebrain
neuronal populations. Second, a portion of cyPrP can be recognized
by the A11 anti-oligomer antibody, indicating that it forms ordered
amyloid oligomer structure. Third, our results indicate that cyPrP is
not invariably aggregated in vivo. When the amount of cyPrP is
above certain threshold, such as in homozygous transgenic mice, a
large portion of it remains soluble in young animals (Fig. 4E and
Supplemental Fig. S4). When cyPrP expression level is below the
threshold, such as in heterozygous transgenic mice, the majority of it
forms aggregates regardless of mouse age (Fig. 2 and Supplemental
Fig. S3).
Neurodegeneration in prion disease occurs in different brain
regions, and thereby our ﬁnding that cyPrP causes toxicity in different
neuronal populations is critical for it to be considered as a legitimate
candidate for the neurotoxic species in prion disease. Since the CamKII
promoter is neuron speciﬁc [26,40] and the fact that we did not
observe extracellular accumulation of cyPrP, the phenotypes observed
here likely result from cell autonomous cyPrP toxicity. The phenotype
in the inducible cyPrP-expressing mice appeared to be milder
compared to what was observed in the cerebellum [15], which could
be attributed to reasons such as a higher resistance of forebrain
neurons to cyPrP toxicity, different mouse background, or the mosaic
expression pattern of the CamKII promoter [26,40]. Nonetheless, our
results clearly revealed that cyPrP is capable to cause forebrain
neurotoxicity, which supports the hypothesis that it may contribute to
neurotoxicity in prion disease.Fig. 7. CyPrP forms ordered amyloid oligomer structure. (A) Forebrain lysates prepared
from induced double transgenic mice (D; pBI-cyPrP-Gal+/+; tTA+/−) or single
transgenic mice (S; pBI-cyPrP-Gal+/+; tTA−/−) were subjected to immunoprecipi-
tationwith or without the anti-oligomer A11 antibody as indicated, and the presence of
cyPrP was detected by immunoblot analysis with the 3F4 antibody (3F4). (B) Same as
those in A. WT, a wild-type mouse; Tg(+/+) represents induced mice that were
homozygous for pBI-cyPrP-Gal transgene; Tg(+/−) represents induced mice that were
heterozygous for pBI-cyPrP-Gal transgene; C represents a control sample in which
forebrain lysate of an induced homozygous transgenic mouse was directly subjected to
immunoblot analysis. As indicated, the presence of cyPrP was detected by immunoblot
analysis with 3F4 antibody, and the same blot was re-probed using POM1 antibody to
detect endogenous PrP.The neurotoxic mechanism of prion disease remains unclear.
Studies of several apoptotic cell death pathways including Bax, Bcl2
and caspase-12 concluded that these pathways do not contribute
signiﬁcantly to the pathogenic process [41–43], revealing the com-
plexity of neurotoxic mechanisms in prion disease. In cyPrP-expres-
sing transgenic mice, neither spongiosis nor PrPSc was detected. This
phenomenon might be due to the low cyPrP expression levels in the
inducible (this study) and the straight transgenic mice [15,28], which
is presumably due to the high neurotoxicity of cyPrP. On the other
hand, it is also possible that the lack of spongiosis or PrPSc is a
characteristic of cyPrP neurotoxicity. Even in this case, cyPrP caused
neurotoxicity may still play a role in the pathogenesis of prion disease.
It is well known that different forms of prion disease differ in clinical
manifestation and pathology [2,22–24], and it is possible that different
pathogenic mechanisms may account for different forms or different
stages of prion diseases. CyPrP induced toxicity, alone or as one of the
toxic components, could be involved in various forms of prion disease,
but its involvement in inherited prion disease seems more appealing.
Several disease-associated PrP mutants have been shown to increase
the retro-translocation of PrP to the cytosol [9,11,44,45]. In addition,
the duration of the inherited prion disease is generally long [2,22–24],
classic PrPSc is not detected in some human cases [24,25,46] or in
animal models [47–49], spongiosis is not evident in some cases
[22,24], and brain atrophy has been reported [46].
One of the interesting ﬁndings in this study is the recognition of
cyPrP by the A11 antibody, indicating that cyPrP may form ordered
oligomeric structures in vivo. Soluble oligomers have been implicated
as the major neurotoxic species in a variety of neurodegenerative
diseases [35]. The formation of soluble cyPrP oligomer may explain
the peculiar relationship between cyPrP aggregation and neurotoxi-
city observed in this study. The homozygous mice differ from their
heterozygous littermates in that the cyPrP level was higher and a large
portion of cyPrP remained soluble in 24-day old mice, suggesting that,
in vivo, a higher cyPrP level does not simply lead to a high degree of
aggregation. The increased cyPrP solubility could be due to that the
intra-neuronal environment in 24-day old mice is unfavorable for
cyPrP to form large aggregates. Alternatively, the cyPrP aggregation
may require its interaction with other intracellular factors that might
be limited in neurons of mice at this age. More importantly, the
increased solubility of cyPrP in 24-day old homozygous mice appears
to correlate with the progression of neurotoxic phenotype. The most
striking difference between homozygous and heterozygous mice is
the smaller body size in homozygous mice, which progresses most
rapidly from 14 days to 4 weeks after birth. After that, the body size of
homozygous mice remains smaller compared to their heterozygous
littermates, but it does not appear to progress any further. Further
study is required to determine whether this phenotype is related to
higher levels of soluble cyPrP oligomers.
Our results are also in accordance with that a low level of cyPrP is
sufﬁcient to cause neurotoxicity and that the cyPrP neurotoxicity
correlates with its interaction with the hydrophobic lipid core of
membranes [15,28]. The neurotoxicity associated with such a small
amount of cyPrP is likely due to its interference with certain vital
physiological processes. Because neurons generally contain long
processes and membrane integrity is critical for their physiological
functions, membrane perturbation would be a plausible explanation
for the impairment of their functionality and viability. The observa-
tions that cyPrP forms ordered oligomeric species that are known to
disrupt lipid bilayer [37,38], and that the cyPrP neurotoxicity
correlates with its interaction with the hydrophobic lipid core of
membranes are in line with this hypothesis. The interaction between
cyPrP and the hydrophobic lipid core of membranes does not
necessarily mean that cyPrP acquires a transmembrane topology.
More likely, it becomes an integral monotopic protein like cyclooy-
genase, which only penetrate one leaﬂet of the lipid bilayer.
Oligomerization of cyPrP in this topological form will likely result in
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microsomal and synaptosomal fractions is consistent with our
previous ﬁnding that cyPrP in cultured cells are associated with ER
and plasma membranes [28]. Because of the high calcium concentra-
tions in ER and extracellular space, permeability alteration in ER and
plasma membranes could potentially lead to a disruption of cytosolic
calcium homeostasis, which may ultimately lead to neurotoxicity.
It is conceivable that cyPrP, which is in a completely foreign
cytoplasmic environment, may cause toxicity via different pathways.
A recent study showed that an oligomeric PrP species, recognized by
the anti-amyloid oligomer antibody and present in partially puriﬁed
PrPSc, reduced proteasome activity by inhibiting the 20S proteasome
catalytic core [50]. We analyzed proteasome activity (including
caspase-like, chymotrypsin-like, and trypsin-like protease activities)
in the inducible transgenic mice at various ages and did not ﬁnd any
signiﬁcant difference between cyPrP-expressing and control mice
(data not shown). However, this negative result does not rule out the
possibility that cyPrP oligomer may compromise proteasome activity
since total forebrain lysates were used in our assay. In the inducible
mice, the expression of cyPrP is determined by the CamKII promoter,
which only expresses in a subset of forebrain neurons [26,51].
Moreover, total forebrain lysates contain not only neurons but also a
large number of other types of cells that may interfere with
proteasome activity analysis. In fact, the peculiar increase of cyPrP
levels during aging (Supplemental Fig. S2) may actually indicate a
decrease in proteasome activity. More detailed studies, such as
crossing our mice with ubiquitin-GFP reporter mice [50], are required
to determinewhether the cyPrP oligomer compromises the ubiquitin–
proteasome degradation system.
Collectively, our results reveal that a low level of cyPrP is sufﬁcient
to cause toxicity in different neuronal populations. Since cyPrP was
detected in cells expressing endogenous wild-type PrP [52] and in
neurons of wild-type mice [8], the cyPrP neurotoxicity may play a role
in various PrP-mediated neurodegenerative disorders.
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